特朗普签署行政命令，加速对伊博根等迷幻药物的联邦研究
Read, Watch or Listen
Washington — On Saturday, President Donald Trump signed an executive order directing the administration to accelerate federal reviews of certain psychedelic drugs, notably ibogaine, and to enable federally funded clinical research into their medical uses. The move follows growing veteran interest and private clinics abroad providing ibogaine treatments to Americans who currently travel for access. This action is intended to speed access to trials and research this year while maintaining ibogaine's Schedule I classification for now, according to federal reports. Immediate consequences include potential federal funding paths, statements of support from veterans and conservative lawmakers, and increased scrutiny of safety risks and regulatory oversight in coming months.
Prepared by Olivia Bennett and reviewed by editorial team.
Timeline of Events
- 长期以来的“表一”指定限制了联邦伊博酮研究。
- 退伍军人团体和私人诊所扩大跨境伊博酮的使用。
- 关于潜在治疗益处与安全风险的争论日益激烈。
- 总统签署行政命令，加速联邦迷幻药审查。
- 各机构为试验准备规程、资助途径和安全监督。
Why This Matters to You
这项命令可能会加速对伊博碱（一种迷幻药物）的研究，从而可能为创伤后应激障碍等疾病带来新的治疗方法。如果您或您所爱的人正在寻求其他选择，请关注临床试验。但请记住，伊博碱仍是一种被列为附表一的药物，存在安全风险。
The Bottom Line
特朗普的命令是探索迷幻剂医疗潜力方面迈出的重要一步。然而，这并未改变伊博碱的法律地位。因此，尽管研究可能会加速，但这并非不设监督使用的通行证。如果您知道有人对替代疗法感兴趣，值得转发。
- Articles Published:
- 4
- Right Leaning:
- 1
- Left Leaning:
- 0
- Neutral:
- 3
- Distribution:
- Left 0%, Center 75%, Right 25%
研究人员、临床试验点以及一些寻求创伤后应激障碍（PTSD）替代疗法的退伍军人，可能会获得更多联邦支持的研究途径和潜在的试验注册机会。
患者在不受控的环境下自行尝试，以及诊所提供不受管制的伊博碱治疗，因已知的安全隐患和在加速审批过程中联邦监管有限，存在受伤的风险。
Coverage of Story:
From Left
No left-leaning sources found for this story.
Comments